Protocol Ledger

NCT05295732 · Phase III · COMPLETED

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Interventional Phase III clinical trial protocol NCT05295732 sponsored by LEO Pharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-21 Enrollment: 153 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05295732
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)153 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05295732
Protocol FieldVerified Registry Value
NCT IdentifierNCT05295732
Consolidated Lead SponsorLEO Pharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment153 participants (ACTUAL)
Registered Start Date2022-06-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI